ALK and inflammatory myofibroblastic tumor: <i>ALK</i> inhibitors such as crizotinib are recommended for <i>ALK</i>-positive IMT and achieve high response rates; however, disease progression may occur, and optimal management after crizotinib failure remains poorly defined.<h4>Case presentation</h4>We report the case of a young adult woman with an <i>ALK</i>-rearranged thoracic IMT harbouring a rare <i>TPR-ALK</i> fusion.